Anti-CEA is employed essentially as a tool to assist in the distinction between adenocarcinoma and epithelioid malignant mesotheliomas,1 along with other markers such as those against calretinin, CK 5&6, CD15, HBME-1, MOC-31, and Ber-EP4.1 Another suggested use of anti-CEA is to immunophenotype various metastatic adenocarcinomas as a means of identifying their origin within a panel of different markers.1 Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix.2,3 Polyclonal anti-CEA is useful in staining hepatocellular carcinoma in a canalicular pattern.2,4